Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 629 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcerative Colitis Clear all
Completed Phase 3 Interventional

Study for the Treatment of Ulcerative Colitis With Adacolumn

NCT00102193
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adacolumn Apheresis System
Device
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Burbank, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2008 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Delayed and extended release mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated Phase 2Phase 3 Interventional

Hyperbaric Oxygen for Ulcerative Colitis

NCT02144350
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hyperbaric oxygen, Sham Hyperbaric Air
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional

Diet Study on Ulcerative Colitis

NCT04147598
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LFD, SAD
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 3 Interventional

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis

NCT00343850
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol (mesalamine)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 22, 2026, 4:01 AM EDT
Not listed Not applicable Interventional

SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis

NCT04398550
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Specific Carbohydrate Diet, Mediterranean Diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 22, 2026, 4:01 AM EDT
Withdrawn Phase 2 Interventional

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission

NCT04259060
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hydroxocobalamin with Butyrate, Placebo with Butyrate
Drug
Lead sponsor
Joshua Korzenik
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 3 Interventional

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

NCT05784246
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab IV, Mirikizumab SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

NCT00033943
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
deligoparin
Drug
Lead sponsor
Incara Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
33
States / cities
Anaheim, California • Orange, California • Lakewood, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

NCT00486031
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide Disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
95
States / cities
Birmingham, Alabama • Tempe, Arizona • Fayetteville, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 22, 2026, 4:01 AM EDT
Not listed Phase 3 Interventional

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

NCT05181137
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated No phase listed Observational

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

NCT00355901
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Visilizumab (Nuvion®; HuM291)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
15
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 22, 2026, 4:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

NCT02100696
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrozulimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 22, 2026, 4:01 AM EDT
Recruiting Phase 2 Interventional

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07845487
View directory record Official record
Conditions
Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
Interventions
PALI-2108, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Sun City, Arizona • San Diego, California • Bristol, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations

NCT02693730
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional

Patient Automated Text Hovering for IBD

NCT04388865
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Control, Text-based Clinical Hovering
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 22, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Not applicable Interventional

Yoga for Youth With IBD: a Pilot Feasibility Study

NCT04757935
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Yoga, Adolescents, Crohn Disease, Ulcerative Colitis
Interventions
Yoga
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated Phase 4 Interventional

Evaluation of Health Costs and Resource Utilization

NCT01960426
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Measurement of drug (Adalimumab/Infliximab), Intensify treatment with the existing drug
Other
Lead sponsor
University of Western Ontario, Canada
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 22, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

NCT04596293
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S or Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Fountain Valley, California • Lancaster, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 22, 2026, 4:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

NCT01164904
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Amg 181
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Glendale, California • Danbury, Connecticut • Plymouth, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 22, 2026, 4:01 AM EDT